The potential of TK1 and TK2 as anti-cancer targets in combination with other pyrimidines de novo synthesis inhibitors has only been demonstrated in vitro so that further in vivo experiments are required to fully understand the potential effect of TKs in cancer. Here, CDC42 is linked to cancer.